Carderock Capital Management Inc. Has $385,000 Stock Holdings in Abbott Laboratories $ABT

Key Points

• Carderock Capital Management Inc. reduced its holdings in Abbott Laboratories by 45.6%, owning 2,900 shares valued at $385,000 after selling 2,435 shares in the latest quarter.
• Abbott Laboratories reported earnings of $1.26 per share, meeting analyst expectations, with revenues of $11.14 billion, up 7.4% year-over-year.
• The company announced a quarterly dividend of $0.59 per share, reflecting an annualized yield of 1.8% and a dividend payout ratio of 29.57%.

Carderock Capital Management Inc. trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 45.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,900 shares of the healthcare product maker's stock after selling 2,435 shares during the quarter. Carderock Capital Management Inc.'s holdings in Abbott Laboratories were worth $385,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories in the first quarter valued at $27,000. Abound Financial LLC acquired a new position in Abbott Laboratories during the 1st quarter worth about $28,000. Elequin Capital LP bought a new stake in shares of Abbott Laboratories in the 1st quarter valued at about $30,000. JCIC Asset Management Inc. acquired a new stake in shares of Abbott Laboratories in the first quarter valued at about $32,000. Finally, Vision Financial Markets LLC bought a new position in shares of Abbott Laboratories during the first quarter worth about $33,000. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Trading Down 1.9%

NYSE:ABT opened at $129.39 on Thursday. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $225.20 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 2.50 and a beta of 0.69. The firm has a fifty day simple moving average of $130.43 and a two-hundred day simple moving average of $131.35.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend was Tuesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is 29.57%.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.46% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ABT shares. Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and upped their target price for the company from $143.00 to $145.00 in a report on Friday, July 18th. Morgan Stanley upped their price objective on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Wells Fargo & Company lowered their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a research note on Friday, July 18th. Leerink Partnrs upgraded shares of Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Finally, BTIG Research decreased their price target on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a report on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $144.47.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.